We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
- Authors
Chang, Susan M; Wen, Patrick; Cloughesy, Timothy; Greenberg, Harry; Schiff, David; Conrad, Charles; Fink, Karen; Robins, H Ian; De Angelis, Lisa; Raizer, Jeffrey; Hess, Kenneth; Aldape, Ken; Lamborn, Kathleen R; Kuhn, John; Dancey, Janet; Prados, Michael D; North American Brain Tumor Consortium and the National Cancer Institute
- Abstract
Loss of PTEN, which is common in glioblastoma multiforme (GBM), results in activation of the mammalian target of rapapmycin (mTOR), thereby increasing mRNA translation of a number of key proteins required for cell-cycle progression. CCI-779 is an inhibitor of mTOR. The primary objectives of this study were to determine the efficacy of CCI-779 in patients with recurrent GBM and to further assess the toxicity of the drug.
- Publication
Investigational new drugs, 2005, Vol 23, Issue 4, p357
- ISSN
0167-6997
- Publication type
Journal Article
- DOI
10.1007/s10637-005-1444-0